Navigation Links
TPI Discusses Non-Cash Non-Operational Financial Impact from Warrants
Date:6/17/2011

CHENGDU, China, June 17, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today discussed the non-cash, non-operational financial impact from the warrants issued in January 2008 under the ASC 815-40-15 (formerly EITF 07-05).

In the financial report of Third quarter fiscal year 2011 ending March 31, 2011, the Company has disclosed that under ASC 815-40-15, the Company's accounting treatment of the Series A and B warrants from July 1, 2009 until December 31, 2010 is subject to revisions. Due to the presence of certain anti-dilutive (down round protection) clauses in both warrants during the above period, these financial instruments have been re-categorized as liabilities while they were previously treated as equity.

On January 14, 2011, these anti-dilutive clauses in both series of warrants were removed therefore the warrants were re-categorized as equity in the third quarter of fiscal year 2011 while the accounting issues related to the warrants ceased to exist.

Based on the warrants' exercise data and weighted valuation, the Company has calculated the non-cash impact for the fiscal year 2010 and the first two quarters of fiscal year 2011. The analysis indicated that

  1. The non-cash impact from the warrants for fiscal year 2010 ending June 30, 2010 was a loss of ($0.16) million, or (1.07%) to pretax net income of $14.7 million
  2. The non-cash impact from the warrants for the first two quarters of fiscal year 2011 was a gain of $1.28 million, or 12.9% to net income for the first two quarters of fiscal year 2011 of $9.9 million.

Management and the Board of Directors of the Company discussed this matter with the Company's principal accountants and de
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. VHGI Discusses Recent Addition to the Regulation SHO Threshold Security Listing
3. Robotic Surgery Expert Dr. David B. Samadi, MD Discusses New Evidence That Proves The Low Complication Rates of Robotic Prostatectomy
4. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
5. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
6. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
7. Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
8. New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer
9. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Staging and Prostate Cancer Recurrence Study
10. Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment
11. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... YORK , Sept. 16, 2014 The ... Foundation (HNF) announced today an agreement to collaborate on ... and support the development of a stronger CMT patient ... financial support to several HNF,s initiatives including: ... in the HNF website featuring  HNF newsletters, materials and ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare and ... Finland , have begun to ... ODM-201, an investigational oral androgen receptor inhibitor in ... in men with castration-resistant prostate cancer who have ... detectable metastases. The trial is designed to determine ...
(Date:9/15/2014)... , Sept. 15, 2014 /CNW/ - Health Minister Rona ... will make available for donation over $2.5 million in personal ... aid in the global response to the Ebola outbreak in ... WHO reported a shortage of equipment in the affected countries ... by front-line workers in the affected countries. ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3
... 28 Having hypertension, or high blood,pressure, reduces blood ... to a new study presented today at the annual ... "While hypertension is not a cause of Alzheimer,s disease, ... brain that increases its vulnerability,to the effects of the ...
... to ... total knee replacement, MINNEAPOLIS, ... of OrthoGlide Medial Knee Implant initial,clinical data., Data representing ... was presented on November 10th, 2007 at the,American College of ...
Cached Medicine Technology:High Blood Pressure May Heighten Effects of Alzheimer's Disease 2Clinical Data Presented on OrthoGlide(R) Medial Knee Implant 2
(Date:9/16/2014)... San Diego, CA (PRWEB) September 16, 2014 ... a new hydrating lip gloss that true-ly pampers lips from ... your lips satin-smooth all day. , “The creation of true ... were suffering from dry, dehydrated lips no matter what products ... that not only looked great on, but could actually hydrate ...
(Date:9/16/2014)... DiaperBuys, a national online retailer of ... this September. Healthy Aging Month was started more than ... on the positive aspects of growing older. , ... side effects from medications that cause urinary incontinence,” explains ... DiaperBuys.com. “This can seem daunting to some patients, especially ...
(Date:9/16/2014)... September 16, 2014 Today, the Diamond ... Icon Awards to be held, Sunday, October 19, 2014 ... The annual awards show honors the dare-devil stuntwomen ... extreme sports stars. Over 12 categories will be ... ESPN’s Kenny Mayne. , Special honors will be ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... monthly specials this month, kicking off September with ... spa in Clearwater, FL chose to highlight lumablanc® ... immediate activation upon contact with the skin. , ... of their best-selling lumafirm® anti-aging line. The brightening ...
(Date:9/16/2014)... 2014 Banish headaches forever with the ... Cefaly device for chronic migraine relief and treatment. Cefaly ... United States. Until now, US patients would directly place ... Belgium and wait 2-3 weeks for their device to ... States and once prescription and payment is received, the ...
Breaking Medicine News(10 mins):Health News:True Science Cosmetics, LLC Launches True Lipz™ 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Hollywood's Action Icon Awards to Honor Legendary Stuntwomen In A Star-Studded Gala and Awards Ceremony 2Health News:Botanica Day Spa Rolls Out September Specials Highlighting Lumablanc® by Pevonia 2Health News:Botanica Day Spa Rolls Out September Specials Highlighting Lumablanc® by Pevonia 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2
... colonised by E. coli bacteria early in life have ... a study of infants carried out at the Sahlgrenska Academy at ... outnumber the cells in our bodies by a factor of ten ... maturation of the immune system. The normal bacterial flora in the ...
... 2012) Autism Speaks is pleased to announce the launch ... in Toddlers, or M-CHAT. The M-CHAT is a scientifically validated ... age to assess their risk for autism spectrum disorder (ASD). ... Fein, Ph.D. and clinical psychologist Marianne Barton, Ph.D. The American ...
... Scientists who found a way to make white fat behave ... new obesity treatments. Brown fat burns energy (preventing obesity), ... cells are associated with fat accumulation around organs in the ... an increased risk for diabetes and heart disease, the researchers ...
... participation in a brief training program designed to ... in how patients perceived their interactions with the ... empathy with patients usually drops during medical school ... of Massachusetts General Hospital (MGH) researchers will appear ...
... against serious pneumococcal disease does not offer full protection, ... of Gothenburg, Sweden, finding that the number of cases ... Each year an estimated 1 million children worldwide die ... those in poor countries, but pneumococcal bacteria cause disease ...
... 6, 2012) - Eye color may be an indicator of ... A study, led by the University of Colorado School of ... have vitiligo. It then follows, according to scientists, that people ... Vitiligo is an autoimmune skin disease in which pigment loss ...
Cached Medicine News:Health News:Gut flora affects maturation of B cells in infants 2Health News:Automated autism screening tool available on Autism Speaks website 2Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: